News
Local
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate News
Hot Property
eNewspaper
________________
Subscriptions
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
Manage Subscription
EZPay
Delivery Issue
eNewspaper
Subscribe
Subscriber Terms
Gift Subscription Terms
About Us
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Contact us
Our Journalism Explained
Newsletters
Readers Rep
Careers
Events
Historical Archives
Podcasts and Livestreams
U-T Store
Events
Advertising
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Place an ad
Media kit
Rate book
Report an ad problem
Cars
Classifieds
Eldercare Directory
Jobs
Newspaper ad directory
Newspaper special sections
Real Estate
Sponsored
Stats Digital
Jobs
CaregiverSD
Community papers
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Del Mar Times
Encinitas Advocate
La Jolla Light
PB Monthly
Point Loma-OB Monthly
Pomerado News
Poway News Chieftain
Ramona Sentinel
Rancho Bernardo
Rancho Santa Fe Review
Games, Puzzles, and Crossword
Crossword
Sudoku
Crossword
Sudoku
Obituaries
Death Notices
Place an obituary
Death Notices
Place an obituary
U-T En Español
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Deportes
Comunidad
Espectáculos
Cierre de Edición, fotos, videos
Noticias
Privacy and Terms
Privacy
Terms
Advertising terms
Privacy
Terms
Advertising terms
Copyright © 2022, The San Diego Union-Tribune |
CA Notice of Collection
|
Do Not Sell My Personal Information
Sections
Sports
Business
Entertainment
Lifestyle
Opinion
Real Estate
Obituaries
eNewspaper
Newsletters
Show Search
Search Query
Submit Search
COVID-19
For subscribers
Phenomenal women
Latino life
Crossword
Sudoku
About Us
Contact us
Community Advisory Board
Readers Rep
Careers
Events
Historical Archives
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
San Diego Stocks
San Diego Stocks
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Ipsen
Ipsen Receives CHMP Negative Opinion for Palovarotene as a Treatment for Fibrodysplasia Ossificans Progressiva in E.U.
January 27, 2023
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Presents Phase III NAPOLI 3 Trial of Onivyde® Regimen Demonstrating Positive Survival Results in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma at ASCO GI
January 20, 2023
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen to Acquire Albireo Accelerating Growth in Rare Disease With Treatments for Several Pediatric Liver Diseases
January 09, 2023
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen receives Complete Response Letter for palovarotene, an investigational treatment for fibrodysplasia ossificans progressiva
December 23, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Provides Update On Phase III CONTACT-01 Trial Evaluating Cabozantinib in Combination With Atezolizumab in Patients With Metastatic Non-small Cell Lung Cancer Previously Treated With Immunotherapy and Chemotherapy
December 08, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Onivyde® Regimen Demonstrated Statistically Significant Improvement in Overall Survival in Previously Untreated Metastatic Pancreatic Ductal Adenocarcinoma
November 09, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
October 27, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Statement on Updated Timeline for Palovarotene FDA Advisory Committee Meeting
October 25, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
August 12, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
August 05, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Announces Results from Phase III RESILIENT Trial Evaluating Onivyde® in Second-Line Monotherapy for Small Cell Lung Cancer
August 03, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen and Marengo Therapeutics Announce Strategic Partnership to Advance Two Precision Immuno-Oncology Candidates From Marengo’s STAR Platform Into the Clinic
August 01, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance
July 28, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission
June 29, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Receives Positive Opinion in Europe for Dysport® in the Management of Urinary Incontinence in Adults With Neurogenic Detrusor Overactivity Due to Multiple Sclerosis or Spinal Cord Injury
June 09, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen: ASCO 2022: New Cabometyx® Data Show Encouraging Results in Monotherapy and in Combination Across Different Tumor Types Including Metastatic Non-Small Cell Lung Cancer
May 26, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen: European Commission Approves Cabometyx® as a Second-Line Treatment for People Living With Radioactive Iodine-Refractory Differentiated Thyroid Cancer
May 03, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Delivers a Strong Sales Performance in the First Quarter Of 2022
April 27, 2022
From
Ipsen
Via
Business Wire
Tickers
IPSEY
OTC
Ipsen Receives Positive CHMP Opinion for Cabometyx® in Radioactive Iodine-refractory Differentiated Thyroid Cancer
March 25, 2022
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen Announces Investment in New State-of-the-Art Electronic Autoinjector for Somatuline® Autogel® / Somatuline® Depot (lanreotide) Designed to Improve Patient Experience
March 16, 2022
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen: Cabometyx® in Combination With Opdivo® Demonstrated Continued Survival and Quality of Life Benefits With Over Two Years of Follow-Up in the Phase III CheckMate -9ER Trial
February 15, 2022
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen Presents Strong Full-Year 2021 Results and Enters Into Exclusive Negotiations to Divest Its Consumer Healthcare Business
February 11, 2022
From
Ipsen
Via
Business Wire
Tickers
OTC
Health Canada Approves Ipsen’s Sohonos™ (palovarotene capsules) as the First Approved Treatment for Fibrodysplasia Ossificans Progressiva
January 24, 2022
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen Nominates Karen Witts as New Independent Board Member
January 21, 2022
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen Appoints Stewart Campbell Executive Vice President and President of North America
November 03, 2021
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen Pledges Ambitious Action on Climate Change
October 27, 2021
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen Delivers Strong Sales Growth for the First Nine Months and Improves Its Full-Year Guidance
October 21, 2021
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen Adds Another Program Into Its Pre-Clinical R&D Oncology Pipeline Through an Exclusive Worldwide Collaboration With Accent Therapeutics, Targeting the RNA Modifying Protein, METTL3
October 18, 2021
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen appoints Mari Scheiffele as EVP and President, Specialty Care International
October 11, 2021
From
Ipsen
Via
Business Wire
Tickers
OTC
Ipsen: ESMO 2021: Cabometyx® Demonstrates Sustained 78% Reduction in Risk of Disease Progression or Death in People Living With Uncommon Form of Thyroid Cancer
September 18, 2021
From
Ipsen
Via
Business Wire
Tickers
OTC
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.